Monopar has been granted in the U.S. and in various countries around the world a patent for antibodies that target uPAR. Monopar has also been granted patents to the MNPR-101 (huATN-658) binding epitope in the U.S., Europe and Japan. Monopar is currently prosecuting this patent in other countries around the world to further protect MNPR-101 (huATN-658).
MNPR-201 (GPX-150) is covered by both composition of matter as well as manufacturing process patents. A novel chemical composition of an intermediate for this synthesis is also patented. In addition, we have a patent covering the combination of MNPR-201 (GPX-150) with paclitaxel for the treatment of cancer, plus covering the method of use of these two drugs for this purpose. Our MNPR-201 (GPX-150) patent portfolio, contains seven issued U.S. patents and allowed patent applications and one U.S. pending patent application. We have certain corresponding patents and applications in twenty-nine foreign jurisdictions, including the United States, E.U., Japan, and other Asian countries. We have obtained U.S. orphan drug status in soft tissue sarcoma.
Validive (clonidine hydrochloride) was designated as an Orphan Medicinal Product for the prevention of severe oral mucositis induced by radio-chemotherapy in head and neck cancer patients in the European Union, enabling optimization of the product’s development plan in terms of cost and duration, as well as strengthening its protection (market exclusivity).
In March 2015, the Japanese Patent Office issued a new patent on Validive (clonidine MBT) . In addition to granted patents in China, South Korea and Singapore, this grant from Japanese authorities significantly strengthens the value of this strategic orphan oncology asset for the Asian market.
In June 2015, the U.S. Patent and Trademark Office (USPTO) allowed a patent covering Validive (clonidine MBT) in the U.S. The U.S. claims cover a new use of clonidine, the active pharmaceutical ingredient of Validive (clonidine MBT) , in the treatment of oral mucositis. Importantly, this patent also covers the use of the mucobuccal adhesive tablet (MBT) formulation of clonidine.